Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review
Shepherd J, Waugh N, Hewitson P
 
 
Record Status

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technology Assessment 2000; 4(33): 1-67
Authors' objectives

To review the clinical effectiveness and cost-effectiveness of combination therapy with interferon alfa and ribavirin in patients with chronic hepatitis C.

Authors' conclusions

There is benefit associated with combination therapy and treatment can be cost-effective. It is appropriate to offer 6 months of combination therapy as first-line treatment to patients not previously treated with interferon and also to patients who have relapsed following a previous course of interferon. At 6 months, continuation of treatment should depend on factors that may predict a good sustained response.

Project page URL
http://www.hta.ac.uk/1178
Indexing Status
Subject indexing assigned by CRD
MeSH
Costs and Cost Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Interferon-alpha; Ribavirin
Language Published
English
Country of organisation
England
Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk
AccessionNumber
32001000002
Date bibliographic record published
03/01/2001
Date abstract record published
03/01/2001
 
Health Technology Assessment (HTA) database
Copyright © 2009 Queen's Printer and Controller of HMSO
 
Homepage
Options
Print
PDF
 
PubMed record
Original research
 
Share
 

Message for HTA database users